642
Views
2
CrossRef citations to date
0
Altmetric
Drug Evaluation

Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature

&
Pages 543-549 | Received 26 Oct 2021, Accepted 19 Jan 2022, Published online: 31 Jan 2022
 

ABSTRACT

Introduction

Invasive aspergillosis is associated with high morbidity and mortality in immunocompromised patients. It is now increasingly reported in critically ill patients, including those with respiratory viral infections, such as influenza and COVID-19. Antifungal management is challenging due to diagnostic delay, adverse drug reactions, drug–drug interactions, narrow therapeutic window, and the emergence of resistance. Isavuconazole is the most recent FDA approved azole for the treatment of invasive aspergillosis, with data continuing to accumulate.

Areas covered

The authors review the safety and efficacy of isavuconazole in the management of invasive aspergillosis based on the currently available evidence. The authors also report on the structure, mechanism of action, pharmacokinetic properties, in vitro and in vivo studies as well as clinical safety and efficacy reports of isavuconazole since its FDA approval.

Expert opinion

Isavuconazole is non-inferior to voriconazole and is a safe, effective, and better tolerated option for the treatment of invasive aspergillosis. It offers several advantages over other antifungal agents, including having a better adverse event profile with respect to hepatotoxicity, neuro-visual toxicity, QTc prolongation, as well as a stable pharmacokinetic profile obviating the need for therapeutic drug monitoring. Further studies are needed to evaluate its performance in prophylaxis against invasive aspergillosis as well as in the treatment of aspergillosis in critically ill patients without underlying cancer or transplant.

Box 1. Drug summary box

Article highlights

  • Invasive aspergillosis is an invasive fungal infection associated with high morbidity and mortality in immunocompromised patients.

  • Isavuconazole is the most recent FDA approved azole for the treatment of invasive aspergillosis.

  • Isavuconazole is non-inferior to voriconazole and is a safe, effective, and better tolerated option for treatment of invasive aspergillosis

  • Isavuconazole offers several advantages over other antifungal agents such as better adverse event profile with respect to hepatotoxicity, neuro-visual toxicity, QTc prolongation, as well as stable pharmacokinetic profile obviating the need for therapeutic drug monitoring

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.